Life Science Investing Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
Life Science Investing Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
Life Science Investing Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
